Korean J Med.
2022 Jan;97(1):60-63. 10.3904/kjm.2022.97.1.60.
Treatment of CD19-Positive Mixed Phenotype Acute Leukemia with Blinatumomab
- Affiliations
-
- 1Division of Hematology-Oncology, Department of Internal Medicine, Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea
- 2Department of Laboratory Medicine, Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea
- KMID: 2525378
- DOI: http://doi.org/10.3904/kjm.2022.97.1.60
Abstract
- Mixed phenotype acute leukemia (MPAL) encompasses a rare group of acute leukemia with blasts expressing markers specific to several lineages, which accounts for 2-5% of all newly diagnosed cases of acute leukemia. At present, patients with MPAL are treated with acute lymphoblastic leukemia (ALL)-directed chemotherapy. However, the prognosis of MPAL, especially in cases of relapsed/refractory (R/R) disease, remains poor. Blinatumomab, a bispecific T cell-engaging antibody, has shown encouraging outcomes in R/R B cell ALL positive for CD19. Here, we report a patient with CD19+ MPAL who achieved complete remission after treatment with blinatumomab, which may be a therapeutic option for patients with relapsed CD19+ MPAL. To our knowledge, this is the first case report of MPAL treated with blinatumomab in Korea.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Immunoglobulin repletion during blinatumomab therapy does not reduce the rate of secondary hypogammaglobulinemia and associated infectious risk
- Immuno-Target Therapy for Relapsed or Refractory Acute Lymphoblastic Leukemia
- A Case of CD45-, CD19- Precursor B Cell Acute Lymphoblastic Leukemia with an Atypical Morphology
- Mixed-phenotype acute leukemia treated with decitabine
- Four Cases of Chronic Myelogenous Leukemia in Mixed Phenotype Blast Phase at Initial Presentation Mimicking Mixed Phenotype Acute Leukemia with t(9;22)
